| Targeting DNA repair in cancer: beyond PARP inhibitors JS Brown, B O'Carrigan, SP Jackson, TA Yap Cancer discovery 7 (1), 20-37, 2017 | 599* | 2017 |
| Bisphosphonates and other bone agents for breast cancer B O'Carrigan, MHF Wong, ML Willson, MR Stockler, N Pavlakis, ... Cochrane database of systematic reviews, 2017 | 485 | 2017 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195, 2020 | 184 | 2020 |
| Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. B O'Carrigan, MJ de Miguel Luken, D Papadatos-Pastos, J Brown, ... Journal of Clinical Oncology 34 (15_suppl), 2504-2504, 2016 | 40 | 2016 |
| Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin … TA Yap, MJM Luken, B O'Carrigan, D Roda, D Papadatos-Pastos, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), PR14-PR14, 2015 | 15 | 2015 |
| Testosterone deficiency and quality of life in A ustralasian testicular cancer survivors: a prospective cohort study B O'Carrigan, M Fournier, IN Olver, MR Stockler, H Whitford, GC Toner, ... Internal Medicine Journal 44 (8), 813-817, 2014 | 14 | 2014 |
| Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g) BRCA and non-BRCA mutant (m) advanced cancer patients … V Michalarea, D Roda, Y Drew, S Carreira, BS O’Carrigan, H Shaw, ... Cancer Research 76 (14_Supplement), CT010-CT010, 2016 | 13 | 2016 |
| Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study E Atallah, SJ Welsh, B O’Carrigan, A Oshaughnessy, I Dolapo, AS Kerr, ... JHEP Reports 5 (10), 100851, 2023 | 12 | 2023 |
| Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: informing clinical studies of VX-970, the first-in-class ATR inhibitor J Pollard, P Reaper, A Peek, S Hughes, S Gladwell, J Jones, P Chiu, ... Cancer Research 76 (14_Supplement), 3717-3717, 2016 | 11 | 2016 |
| Targeting DNA repair in Cancer: beyond PARP inhibitors. Cancer Discov. 2017; 7: 20–37 JS Brown, B O’Carrigan, SP Jackson, TA Yap | 8 | |
| The different faces of metastatic melanoma in the gastrointestinal tract EM Serrao, AM Costa, S Ferreira, V McMorran, E Cargill, C Hough, ... Insights into Imaging 13 (1), 161, 2022 | 6 | 2022 |
| Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 7 (1): 20–37 JS Brown, B O’Carrigan, SP Jackson, TA Yap | 6 | 2017 |
| REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers S Merrick, M Nankivell, M Quartagno, CS Clarke, N Joharatnam-Hogan, ... Contemporary clinical trials 124, 107030, 2023 | 4 | 2023 |
| The forgotten appearance of metastatic melanoma in the small bowel E Mendes Serrao, E Joslin, V McMorran, C Hough, C Palmer, ... Cancer Imaging 22 (1), 27, 2022 | 3 | 2022 |
| A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma. EJ Dean, U Banerji, R Girotti, I Niculescu-Duvaz, F Lopes, L Davies, ... Journal of Clinical Oncology 34 (15_suppl), TPS9597-TPS9597, 2016 | 3 | 2016 |
| Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre B O’Carrigan, JSJ Lim, A Jalil, SJ Harris, D Papadatos-Pastos, U Banerji, ... British journal of cancer 119 (8), 922-927, 2018 | 2 | 2018 |
| Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy AJ Lomax Number 4/August 2017 21 (4), E93-E98, 2017 | 2 | 2017 |
| Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH). SJ Harris, B O'Carrigan, JS Lopez, J Bhosle, U Banerji, S Popat, ... Journal of Clinical Oncology 34 (15_suppl), e14048-e14048, 2016 | 2 | 2016 |
| Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU). B O'Carrigan, A Jalil, D Papadatos-Pastos, SJ Harris, JS Lopez, U Banerji, ... Journal of Clinical Oncology 34 (15_suppl), 11508-11508, 2016 | 1 | 2016 |
| Patient with a rash, abdominal pain, and weight loss B O’Carrigan, JY Cheong JAMA 307 (8), 843-844, 2012 | 1 | 2012 |
